TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 70585

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (600 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (150 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study: 31568109

Group type: EXPERIMENTAL
Intervention: Online education only
Number of subjects: 100

Group type: COMPARATOR
Intervention: Online education plus a 3-hour face-to-face training session
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Online education only and Online education plus face-to-face)
Number of subjects: 100
Study: 29187391

Group type: EXPERIMENTAL
Intervention: Implicit gender bias measured by Implicit Association Test
Number of subjects: 503
Study: 25150913

Group type: EXPERIMENTAL
Intervention: True facilitative KinTape
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham KinTape
Number of subjects: 30

Group type: COMPARATOR
Intervention: No KinTape
Number of subjects: 30
Study: 23294034

Group type: EXPERIMENTAL
Intervention: EFV 600 mg once daily
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: AZV/r 300 mg and ritonavir 100 mg once daily
Number of subjects: 245

Group type: COMPARATOR
Intervention: LPV/r 400 mg and ritonavir 100 mg twice daily
Number of subjects: 245
Study: 21812910

Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of ketamine 1 mg/kg (Group KS1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of ketamine 2 mg/kg (Group KS2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 1 mg/kg (Group KI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Subcutaneous infiltration of normal saline 20 mL (Group C)
Number of subjects: 120
Study: 18194386

Group type: EXPERIMENTAL
Intervention: Leukoreduced red blood cell (RBC) transfusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buffy coat-depleted red blood cell (RBC) transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma (FFP) transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MBL deficiency (MBL ≤ 80 ng/mL)
Number of subjects: 0
Study: 16472564

Group type: EXPERIMENTAL
Intervention: Group 1 - Initial injection on 1st-5th day of menstrual cycle, subsequent injections every 30 +/- 3 days.
Number of subjects: 365

Group type: COMPARATOR
Intervention: Group 2 - Initial injection between Days 7 and 10 of menstrual cycle, subsequent injections 7-10 days after Day 1 of withdrawal bleeding.
Number of subjects: 365
Study: 12702997

Group type: EXPERIMENTAL
Intervention: Low helical pitch acquisition (3:1)
Number of subjects: 384

Group type: COMPARATOR
Intervention: High helical pitch acquisition (6:1)
Number of subjects: 384
Study: 10473015

Group type: EXPERIMENTAL
Intervention: Frequent testing (twice per week) for 10 weeks
Number of subjects: 166

Group type: COMPARATOR
Intervention: Less frequent testing (approximately weekly or every 3-4 weeks)
Number of subjects: 166
Study: 8738729

Group type: COMPARATOR
Intervention: Propranolol alone (n = 19)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propranolol plus molsidomine (n = 15)
Number of subjects: 34
Study: 1742750

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7020778

Group type: EXPERIMENTAL
Intervention: Contingent EMG biofeedback from the forehead area
Number of subjects: 24

Group type: COMPARATOR
Intervention: Noncontingent EMG feedback from a tape recorder (single blind)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Auditory feedback (yoked control)
Number of subjects: 24
Study: 31133406

Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion stimulation
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 1078
Study: 27125223

Group type: EXPERIMENTAL
Intervention: Predictive low glucose suspend (PLGS) system
Number of subjects: 127
Study: 25240630

Group type: EXPERIMENTAL
Intervention: Ocriplasmin 125 μg
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 23685525

Group type: EXPERIMENTAL
Intervention: Aquacel Ag
Number of subjects: 24

Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 24
Study: 21242674

Group type: EXPERIMENTAL
Intervention: Oral paricalcitol
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 227
Study: 18940282

Group type: EXPERIMENTAL
Intervention: Proteinuria present (750 patients)
Number of subjects: 5835

Group type: COMPARATOR
Intervention: No proteinuria (5,085 patients)
Number of subjects: 5835

Group type: EXPERIMENTAL
Intervention: Low-grade proteinuria
Number of subjects: 5835

Group type: EXPERIMENTAL
Intervention: High-grade proteinuria
Number of subjects: 5835
Study: 16493123

Group type: EXPERIMENTAL
Intervention: Red wine (450 mL daily, 40 grams of alcohol)
Number of subjects: 34

Group type: COMPARATOR
Intervention: De-alcoholized red wine (450 mL daily)
Number of subjects: 34
Study: 12889564

Group type: EXPERIMENTAL
Intervention: Group-based educational intervention for IBD patients (8 sessions)
Number of subjects: 49
Study: 10859007

Group type: EXPERIMENTAL
Intervention: Low fat, low lactose diet
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 143
Study: 9453117

Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation of lower uterine segment (LUS) thickness
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation of LUS thickness with a criterion of 2 mm or less for poor healing
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation of LUS thickness in women with poor healing
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation of LUS thickness in women with 2 mm LUS thickness
Number of subjects: 123
Study: 7938237

Group type: EXPERIMENTAL
Intervention: MSG with 0.5 mM inosine‐5'‐monophosphate (IMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSG alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: MSG
Number of subjects: 0
Study: 3356357

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate
Number of subjects: 135

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 135
Study: 29473358

Group type: EXPERIMENTAL
Intervention: Guiding-qi acupuncture combined with electroacupuncture (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture (control group)
Number of subjects: 60
Study: 27164691

Group type: EXPERIMENTAL
Intervention: Vitamin E (1,000 IU orally twice daily for 3 years)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo (identical to vitamin E)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 25691084

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 14
Study: 23850555

Group type: EXPERIMENTAL
Intervention: Endoscopic screening for colorectal cancer (CRC) with assumed medium adherence (70%) and contamination (30%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic screening for colorectal cancer (CRC) with low adherence (50%) and high contamination (50%)
Number of subjects: 0
Study: 20572374

Group type: EXPERIMENTAL
Intervention: Chitin‐PAA dressing
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lipido‐colloid absorbent dressing
Number of subjects: 36

Group type: COMPARATOR
Intervention: Alginate wound dressing
Number of subjects: 36
Study: 18194407

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study: 16627836

Group type: EXPERIMENTAL
Intervention: Nebulisation with a combination of salbutamol (0.5 mg) and magnesium sulphate (500 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nebulisation with salbutamol only (0.5 mg)
Number of subjects: 100
Study: 11903240

Group type: EXPERIMENTAL
Intervention: Emulsifying ointments (unguentum emulsificans and dilutions with 30, 50, 70 and 90% aqua purificans)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Negative control (no treatment)
Number of subjects: 10
Study: 9860106

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 4 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg and 4 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (various doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7617137

Group type: EXPERIMENTAL
Intervention: GHRP (4 x 50 micrograms i.v. boluses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study: 2198165

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT) at increasing doses (50-1,500 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT) at daily 3,000 mg doses for 1 week
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 320654

Group type: EXPERIMENTAL
Intervention: Ampicillin pediatric suspension (100 mg ampicillin/kg/24 hours divided in 4 doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pivampicillin base pediatric suspension (64.8 mg/kg/24 hours divided in 4 doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 16
Study: 6752082

Group type: EXPERIMENTAL
Intervention: nomifensine
Number of subjects: 27

Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 27
Study: 30895713

Group type: EXPERIMENTAL
Intervention: PLGA-coated biphasic calcium phosphate particles (group I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncoated biphasic calcium phosphate particles (group II)
Number of subjects: 0
Study: 29575043

Group type: EXPERIMENTAL
Intervention: 1-day group workshop intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 100
Study: 26220315

Group type: EXPERIMENTAL
Intervention: Psychological support from a professional psychologist during pre-operative visit, hospitalisation, and rehabilitation.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 200
Study: 23489888

Group type: EXPERIMENTAL
Intervention: Dual therapy (aspirin 75‐160 mg daily and clopidogrel 300 mg day 1 then 75 mg daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Monotherapy (aspirin 75‐160 mg daily)
Number of subjects: 65
Study: 22829901

Group type: EXPERIMENTAL
Intervention: Fully maturated cheese (Parmigiano‐Reggiano; PR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cow's milk (CM)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Digested PR preparations
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: IgE to BLG measured by ISAC
Number of subjects: 70
Study: 19323872

Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard light
Number of subjects: 0
Study: 17612824

Group type: EXPERIMENTAL
Intervention: Individual Brief Therapeutic Phone Contacts (IBTPC) integrating motivational interviewing and cognitive behavioral therapies
Number of subjects: 43
Study: 15197430

Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized fiber (PMX-F) treatment (n=15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional treatment (n=10)
Number of subjects: 25
Study: 12076241

Group type: EXPERIMENTAL
Intervention: Hormone/estrogen replacement therapy (H/ERT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 9874467

Group type: EXPERIMENTAL
Intervention: Epoetin alfa administration for patients receiving cisplatin chemotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epoetin alfa administration for patients receiving noncisplatin chemotherapy
Number of subjects: 100
Study: 7622259

Group type: EXPERIMENTAL
Intervention: 5-day antibacterial therapy (Penicillin 300 mg/kg for meningococcal and pneumococcal meningitis; Ampicillin 300 mg/kg for Haemophilus influenzae b meningitis)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5-day antibacterial therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (8 to 15 days of antibacterial therapy)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 1978492

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 12
Study: 318898

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vitamin C absence
Number of subjects: 20
Study: 31357534

Group type: EXPERIMENTAL
Intervention: Functional VOO enriched with olive oil PCs (500 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Functional VOO enriched with olive oil (250 mg/kg) and thyme PCs (250 mg/kg; FVOOT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Natural VOO (control intervention; olive oil PCs: 80 mg/kg)
Number of subjects: 22
Study: 27620949

Group type: EXPERIMENTAL
Intervention: Malleable factors (peer connections, received friendships)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Malleable factors (class size, autism symptom severity, peer connections)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Malleable factors (autism symptom severity, peer connections, received friendships)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Age (stable factor)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: No stable factors (age, IQ, sex)
Number of subjects: 148
Study: 26110375

Group type: EXPERIMENTAL
Intervention: Naloxone sustained release (NSR) 2.5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Naloxone sustained release (NSR) 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Naloxone sustained release (NSR) 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Naloxone sustained release (NSR) 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24313686

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Blue-red light-emitting diode (LED) phototherapy
Number of subjects: 150
Study: 23095782

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS)
Number of subjects: 21
Study: 19671333

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) therapy, n = 70
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (without TMZ), n = 68
Number of subjects: 138
Study: 17901793

Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanate
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 75
Study: 15140463

Group type: EXPERIMENTAL
Intervention: Pain management intervention (PMI)
Number of subjects: 189
Study: 12194936

Group type: EXPERIMENTAL
Intervention: Riboflavin (1.6 mg/day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 11072399

Group type: EXPERIMENTAL
Intervention: Chart reminders (Condition B)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Posted memos (Condition A1)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Posted memos (Condition A2)
Number of subjects: 81
Study: 8577657

Group type: COMPARATOR
Intervention: Normal pregnancies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PECAM, ICAM-1, and ICAM-2 mRNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E-Selectin and VCAM-1 mRNA
Number of subjects: 0
Study: 2171846

Group type: EXPERIMENTAL
Intervention: Guanadrel sulfate (3 weeks treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (3 weeks treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study: 619817

Group type: COMPARATOR
Intervention: Carmustine and fluorouracil (two-drug regimen)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Carmustine, fluorouracil, and spironolactone (three-drug regimen)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Three-drug regimen (carmustine, fluorouracil, spironolactone)
Number of subjects: 38
Study: 31703056

Group type: EXPERIMENTAL
Intervention: Percutaneous Transforaminal Endoscopic Discectomy (PTED)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Microendoscopic Discectomy (MED)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: PTED
Number of subjects: 250

Group type: COMPARATOR
Intervention: MED
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: PTED and MED
Number of subjects: 250
Study: 30642911

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/bevacizumab (PCB)
Number of subjects: 223
Study: 26888327

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 748

Group type: COMPARATOR
Intervention: Neutral health message (control)
Number of subjects: 748
Study: 25388765

Group type: EXPERIMENTAL
Intervention: Commercially‐available herbal dentifrice
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 5% non‐herbal potassium nitrate
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 145
Study: 24603308

Group type: EXPERIMENTAL
Intervention: Contrast-induced acute kidney injury (CI-AKI)
Number of subjects: 2968
Study: 23283047

Group type: EXPERIMENTAL
Intervention: Butenafine (BTF)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bifonazole (BFZ)
Number of subjects: 96
Study: 19853193

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV6/11/16/18 vaccine
Number of subjects: 679

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 679
Study: 17451419

Group type: EXPERIMENTAL
Intervention: Near patient testing for glycated haemoglobin
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual laboratory test (Control)
Number of subjects: 344
Study: 15206665

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (15-mg nicotine patch, 4-mg nicotine gum, and/or 10-mg nicotine inhaler)
Number of subjects: 923

Group type: COMPARATOR
Intervention: Placebo products
Number of subjects: 923

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 923
Study: 11409480

Group type: EXPERIMENTAL
Intervention: Methotrexate (25 mg, n=9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hyperosmolar glucose (50%, n=9)
Number of subjects: 20
Study: 9745800

Group type: EXPERIMENTAL
Intervention: Progressive relaxation with stress management training
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cephalic vasomotor feedback with stress management training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Metoprolol (beta-blocker)
Number of subjects: 43
Study: 8201564

Group type: EXPERIMENTAL
Intervention: Collagen shields saturated with an antibiotic and a steroid placed in 90 eyes postoperatively
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group received the same drugs through a peribulbar/retrobulbar injection in 93 eyes
Number of subjects: 183
Study: 3322763

Group type: EXPERIMENTAL
Intervention: Preparation B (Euthyrox)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preparation A (L-Thyroxin Henning)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preparation C (Levothyroxine, enos)
Number of subjects: 0
Study: 30200088

Group type: EXPERIMENTAL
Intervention: TENS on peroneal nerve at 1 Hz
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TENS on peroneal nerve at 5 Hz
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TENS on soleus muscle at 5 Hz
Number of subjects: 24
Study: 27054826

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression (BATD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 46
Study: 23949727

Group type: EXPERIMENTAL
Intervention: 30 mL contrast medium (G30)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 40 mL contrast medium (G40)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 50 mL contrast medium (G50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 60 mL contrast medium (G60)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 70 mL contrast medium (G70)
Number of subjects: 100
Study: 23007724

Group type: EXPERIMENTAL
Intervention: Voluntary rhythms of each hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticomuscular coherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interhemispheric delays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticomuscular delays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15-30 Hz corticomuscular coherence during isometric contractions
Number of subjects: 0
Study: 20434204

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg daily (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 36
Study: 18565860

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice a day
Number of subjects: 627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study: 16095415

Group type: EXPERIMENTAL
Intervention: Altitude (AL) condition (P(I)o(2) = 123.1 mm Hg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sea Level Control (SLC) condition (P(I)o(2) = 147.3 mm Hg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Altitude (AL) condition
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sea Level Control (SLC) condition
Number of subjects: 20
Study: 12584827

Group type: EXPERIMENTAL
Intervention: Kangxian Baogan Decoction (KXBGD)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional liver protecting treatment
Number of subjects: 81
Study: 10512280

Group type: EXPERIMENTAL
Intervention: 40 mL epidural saline flush
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 mL epidural saline flush
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no saline flush)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 8